References
- Khalid AN, Hunt J, Perloff JR, Kennedy DW: The role of bone in chronic rhinosinusitis. Laryngoscope 2002;112:1951 https://doi.org/10.1097/00005537-200211000-00008
- Marx RE: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115 https://doi.org/10.1016/S0278-2391(03)00720-1
- Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL: Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527 https://doi.org/10.1016/j.joms.2004.02.004
- Kwon Y-D, Yoon B-W, Walter C: Bisphosphonate, is it an emerging risk factor in oral surgery? J Korean Assoc Maxillofac Plast Reconstr Surg 2007;29:456
- Walter C, Grotz KA, Kunkel M, Al-Nawas B: Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 2007;15:197 https://doi.org/10.1007/s00520-006-0120-z
- Koulocheris P, Weyer N, Liebehenschel N et al.: Suppurative maxillary sinusitis in patients with bisphosphonate-associated osteonecrosis of the maxilla: report of 2 cases. J Oral Maxillofac Surg 2008;66:539 https://doi.org/10.1016/j.joms.2007.05.014
- Legert KG, Zimmerman M, Stierna P: Sinusitis of odontogenic origin: pathophysiological implications of early treatment. Acta Otolaryngol 2004;124:655 https://doi.org/10.1080/00016480310016866
- Marx RE, Sawatari Y, Fortin M, Broumand V: Bisphosphonateinduced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567 https://doi.org/10.1016/j.joms.2005.07.010
- Rosen HN, Moses AC, Garber J et al.: Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000;66:100 https://doi.org/10.1007/PL00005830